

Redefining the Roles of Antithrombotic and Antiplatelet Therapies in Reducing CAD and PAD Residual Risk

Dear Grand Rounds Administrator:

In conjunction with the Annenberg Center for Health Sciences at Eisenhower, Postgraduate Institute for Medicine, and Medtelligence, we are pleased to announce an exciting CME-certified Grand Rounds program.

This case-based program will bring a distinguished specialist to your center to provide evidence-based information and guidance on the use of antithrombotic medication in patients with polyvascular disease. The target audience includes cardiologists, interventional cardiologists, internists, fellows, medical students, pharmacy professionals, and allied health professionals involved in the care of patients with polyvascular disease.

The Learning Objectives are designed to enhance participants' ability to:

- Describe the rationale for combining an anticoagulant with antiplatelet therapy after stenting
- Relate the clinical implications of anticoagulation in patients with coronary artery disease (CAD), peripheral artery disease (PAD), and other vascular diseases
- Utilize non-vitamin K oral anticoagulants (NOACs) at the proper dose for patients with moderate or high risk of major polyvascular events, advising patients of the risks and benefits, and performing proper follow-up
- Apply guideline recommendations for secondary prevention of CAD after ACS or PCI and discuss the proposed changes that have been recommended

This program is jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Medtelligence in collaboration with Postgraduate Institute for Medicine. It is certified for *AMA PRA Category 1 Credit™* and is supported by an unrestricted educational grant from Janssen Scientific Affairs. Please note that Janssen had no input in the faculty selection or content.

We hope your institution will take advantage of this important teaching initiative.

Sincerely,



Roxana Mehran, MD

Professor of Medicine (Cardiology) and Population Health Science and Policy
Director of Interventional Cardiovascular Research and Clinical Trials
Zena and Michael A. Weiner Cardiovascular Institute
Icahn School of Medicine at Mount Sinai



Ben Caref, PhD

Managing Partner
Chief Medical Officer
Medtelligence



Redefining the Roles of Antithrombotic and Antiplatelet Therapies in Reducing CAD and PAD Residual Risk

Clinical Overview

The introduction of non-VKA oral anticoagulants (NOACs) into clinical practice has produced a wealth of data, changed guideline recommendations, and continues to push into new areas where an anticoagulation strategy may supplement or replace current thrombocardiology strategies for polyvascular protection from clot formation and embolization. There is a need to evaluate the data, clinical implications, and recommendations in secondary prevention of coronary artery disease (CAD) and peripheral artery disease (PAD) where an antiplatelet + anticoagulation management strategy has increasingly benefited patients by protecting against clot formation and embolization with NOACs, while keeping bleeding risks acceptable.

Grand Rounds Program

This case-based educational program is designed by distinguished experts in the field to provide the healthcare professional information and guidance on the clinical issues and recent data regarding anticoagulation in patients with CAD and PAD.

Target Audience

Cardiologists, interventional cardiologists, internists, fellows, medical students, pharmacy professionals, and allied health professionals involved in the care of patients with CAD and PAD.

Learning Objectives

- Describe the rationale for combining an anticoagulant with antiplatelet therapy after stenting
- Relate the clinical implications of anticoagulation in patients with CAD, PAD, and other vascular diseases
- Utilize NOACs at the proper dose for patients with moderate or high risk of major polyvascular events, advising patients of the risks and benefits, and performing proper follow-up
- Apply guideline recommendations for secondary prevention of CAD after ACS or PCI and discuss the proposed changes that have been recommended

Joint Providership

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Medtelligence in collaboration with Postgraduate Institute for Medicine (PIM).

Support

Supported by an independent medical educational grant from Janssen Scientific Affairs, LLC.

Program Administration

Medtelligence

Physician Continuing Education Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Medtelligence. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation through Annenberg Center and PIM

For Annenberg Center/PIM to accredit a lecture at your institution, the following Medtelligence-supplied documents must be completed and returned to Medtelligence at the conclusion of the program: Sign-in sheet and Evaluations.

Disclosure of Conflicts of Interest

The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

To request a program, please complete the attached **Program Request Form (PRF)** and refer to the list of faculty members (also attached) to indicate your speaker preference. Please fax or email the completed PRF to:

FAX: 206-333-1106

EMAIL: jfreeman@medtelligence.net

Please contact Jill Freeman with any questions: jfreeman@medtelligence.net

Redefining the Roles of Antithrombotic and Antiplatelet Therapies in Reducing CAD and PAD Residual Risk

FACULTY

Dominick J. Angiolillo, MD, PHD

Professor of Medicine
Medical Director, Cardiovascular Research Program
Program Director, Interventional Cardiology Fellowship Program
Associate Program Director, Cardiovascular Disease Fellowship
University of Florida College of Medicine - Jacksonville
Jacksonville, FL

Deepak L. Bhatt, MD, MPH

Executive Director, Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, MA

William E. Boden, MD

Professor of Medicine, Boston University School of Medicine
Lecturer in Medicine, Harvard Medical School
Physician Research Lead & Scientific Director, Clinical Trials Network
VA New England Healthcare System
Boston, MA

Marc P. Bonaca, MD, MPH

Medical Director, Aortic Disease Center, Brigham and Women's Hospital
Assistant Professor of Medicine, Harvard Medical School
Investigator, TIMI Study Group
Boston, MA

James de Lemos, MD

Professor of Internal Medicine, Division of Cardiology
UT Southwestern Medical Center
Dallas, TX

Nihar R. Desai, MD, MPH

Assistant Professor of Medicine, Cardiovascular Medicine Section
Yale School of Medicine
Investigator, Center for Outcomes Research and Evaluation
New Haven, CT

Mark B. Efron, MD

Consultant Cardiologist, John Ochsner Heart and Vascular Institute
Medical Director for Research, Ochsner Health System
Associate Professor, Ochsner Clinical School
New Orleans, LA

Redefining the Roles of Antithrombotic and Antiplatelet Therapies in Reducing CAD and PAD Residual Risk

FACULTY, *cont.*

Dharam Kumbhani, MD, SM

Associate Professor, Interventional Cardiology, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, TX

Roxana Mehran, MD

Professor of Medicine (Cardiology) and Population Health Science and Policy
Director of Interventional Cardiovascular Research and Clinical Trials
Zena and Michael A. Weiner Cardiovascular Institute
Icahn School of Medicine at Mount Sinai
New York, NY

L. Kristin Newby, MD, MHS

Professor of Medicine, Cardiology
Co-Director, Duke Cardiac Intensive Care Unit
Senior Faculty, Duke Clinical Research Institute
Duke University School of Medicine
Durham, NC

Michelle L. O'Donoghue, MD, MPH

Associate Professor of Medicine, Harvard Medical School
Associate Physician, Cardiovascular Division, Brigham and Women's Hospital
Boston MA

Gregory Piazza, MD, MS

Assistant Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women's Hospital
Boston, MA

Binita Shah, MD, MS

Assistant Professor of Medicine, Leon H. Charney Division of Cardiology (Interventional Cardiology)
Associate Director, Cardiac Cath Lab Research
New York University School of Medicine
New York, NY

Tracy Y. Wang, MD, MHS, MS

Associate Professor of Medicine
Director of Health Services Research
Duke Clinical Research Institute
Duke University
Durham, NC

Jeffrey Weitz, MD

Professor of Medicine & Biochemistry and Biomedical Sciences, McMaster University
Executive Director, Thrombosis and Atherosclerosis Research Institute
Hamilton, ON, Canada

Redefining the Roles of Antithrombotic and Antiplatelet Therapies in Reducing CAD and PAD Residual Risk

Program Request Form

<p>Hospital/University Contact Name & Title:</p> <p>Contact Phone:</p> <p>Contact Fax:</p> <p>Department:</p> <p>Department Head:</p> <p>Department Head Title:</p> <p>Hospital/University Name:</p> <p>Hospital's Academic Affiliation:</p> <p>Address:</p> <p>City, State, Zip:</p> <p>Email:</p> <p>Proposed Dates:</p> <p>Start Time: _____ AM / PM (Duration=1 hour)</p> <p>Estimated Audience:</p> <p>Audience Specialty:</p> <p>Lecture Location/Room:</p> <p>Additional Comments:</p>	<p>Speaker Preference:</p> <hr/> <p>Will Annenberg Center/PIM certify your program?</p> <p>_____ Yes _____ No</p> <p>If yes, we will produce flyers for distribution prior to the lecture. Please complete the required Flyer Information Form attached.</p> <hr/> <p>Will speaker honoraria be paid by Medtelligence or the hospital?</p> <p>_____ Medtelligence</p> <p>_____ Hospital (Medtelligence will provide the check)</p> <p>If through the hospital, please supply the following:</p> <p>Payee Name:</p> <p>Tax ID#:</p>
--	---

**PLEASE FAX OR EMAIL THE COMPLETED PROGRAM REQUEST FORM
(AND FLYER INFORMATION FORM, IF APPLICABLE)**

FAX: 206-333-1106

EMAIL: jfreeman@medtelligence.net

Redefining the Roles of Antithrombotic and Antiplatelet Therapies in Reducing CAD and PAD Residual Risk

Flyer Information Form

Day of Week:

Date:

Start time: _____ AM / PM
(Duration = 1 hour)

Name of Lecture Institution:

Floor/Room Number:

Room Name:

Street Address:

City, State, Zip:

For more information, contact:

At phone number or email:

If you are requesting CME credit through Annenberg Center/PIM, you must complete this form and fax back with your **Program Request Form** attached. Flyers are required.

**PLEASE FAX OR EMAIL THE COMPLETED FLYER
INFORMATION FORM
(AND PROGRAM REQUEST FORM)**

**FAX: 206-333-1106
EMAIL: jfreeman@medtelligence.net**